The Covid-19 vaccine from Pfizer and BioNTech protects against two new mutant variants that are causing rapid spread across the UK, new research suggests.
The pharmaceutical giant and researchers from the University of Texas Medical Branch carried out lab tests on the strains, one of which was found in the UK while the other originated in South Africa.
The variants contain mutations including N501Y, an alteration in the spike protein of the virus, which is a target for vaccines.
In the new study, which has not yet been peer-reviewed, blood samples were taken from 20 people who received the Pfizer vaccine.
Laboratory studies found that the samples had neutralising levels of antibodies which appeared to work against the new strains.
The third lockdown in England was in response to the rapid spread of the mutant strain found in the South East, which has now spread to other parts of the UK.
Pfizer has now tested 16 different mutations in the strains and none of them have had any significant impact on how the vaccine works.
However, further studies are planned on other mutations.
Support The Courier today.
The Courier is committed to delivering quality content to our communities and right now that’s more important than ever — which is why our key content is free. However, you can support us and access premium content by subscribing to The Courier from just £5.99 a month. Because Local Matters.Subscribe